The Fab’entech biopharmaceutical company Fab’entech is launching the production of its treatment against Ebola.

Fab'entech, specialising in the treatment of emerging infectious diseases for 5 years, is offering passive anti-infective immunotherapy solutions based on specific and highly-purified polyclonal antibodies.

Lyon, dated 09 February 2015:
Recognised for its production capacities, its short development lead times and the quality of its products, Fab’entech has accelerated its project to develop a treatment against Ebola, in collaboration with the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).

These highly-purified antibodies for use in humans aim to specifically and immediately neutralise the virus and to slow down disease progression, alongside the vaccination and antiviral strategies under development.

Invited last week to the inauguration of the first BSL-4 high-containment laboratory in Wuhan, China, in the presence of Official Representatives of the French delegation, and to the associated Ebola symposium, Dr Bertrand Lépine, Chairman of the Management Board of Fab’entech, confirmed his commitment to the fight against Ebola: “Today, we are launching the production of our anti-Ebola treatment and we expect it to be available in the summer of 2015, as part of clinical development or compassionate use.”

Fab’entech is thus participating in the international mobilisation launched in response to the unprecedented epidemic in West Africa. The Fab’entech product will therefore be ready to respond to any Ebola-related health emergency.

Fab’entech bases the development and production of its products on a platform established from a licence of the Sanofi Pasteur’s technology, complemented by collaboration and subcontracting contracts.


Bio-production: Fab’entech presents its new industrial site

Fab’entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab’entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV®) in France. Close-up of this new site, a key asset in the development of the biotech’s activities.